The €4.10 per share mandatory takeover offer for Wilex from its largest shareholder, dievini Hopp BioTech, undervalues the Munich-based biopharmaceutical company, said its executive management and supervisory boards.

In a joint response.....

AstraZeneca reported a modest 1% increase in revenue for the second quarter to $8.2 billion at constant exchange rates, following a 4% drop in US revenue chiefly as a result of generic competition for Toprol-XL (metoprolol succinate),.....

Sanofi-Aventis is reportedly set to make an offer for Genzyme after posting a 61% rise in second-quarter net income to €1.8 billion.

The French firm's CEO Chris Viehbacher refused to "comment on specifics" but reiterated to.....

AstraZeneca gained substantial support on 28 July from the US FDA's advisory committee on cardiovascular and renal drugs for its potential blockbuster blood thinner Brilinta (ticagrelor). Panellists voted seven to one to recommend approval.....

With a strong balance sheet including £34 million in cash and significant reductions in operating costs and losses, Vernalis is now in a position to focus on rebuilding shareholder value, the company said.

This three-tier.....

Strong second-quarter performances from Merck KGaA's leading products coupled with its recent acquisition of Millipore, led the German firm to raise its full-year revenue growth guidance to 21% and its expected operating result growth rate.....

Alliance Boots has raised its stake in Hedef Alliance Holding, one of Turkey's largest pharmaceutical wholesalers, from 50% to 60%, becoming its majority shareholder. Hedef's founder Ethem Sancak will remain its executive chairman.

Alliance.....

Victims from Australia and New Zealand of the birth-defect drug thalidomide have reached an agreement with UK beverage firm Diageo which will see it give out A$50 million in compensation.

Diageo took over Distillers Company which had been the.....

The publication of the pivotal IMPACT trial of Dendreon's Provenge (sipuleucel-T) in the NEJM has highlighted that many questions still surround the first therapeutic vaccine to be approved in the US.

In April, the FDA.....

Bayer saw group sales grow by 15% in the second quarter to €9.2 billion, and confirmed its outlook for the full year. This comes despite Bayer downwardly revising its sales forecast for its healthcare division following the.....

NICE, the health technology appraisal institute in England and Wales, will reappraise Celgene's Vidaza (azacitidine) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia following several appeals against.....

In a difficult financial year dominated by the failure of its lead anticancer candidate ASA404, Antisoma reported a net loss of £18.7 million, or 3.0p per diluted share, compared with a £16.4 million loss, or 2.7p per diluted.....

The US FDA has approved Shionogi Pharma's Cuvposa (glycopyrrolate) for the treatment of severe drooling (ptyalism) caused by neurologic disorders in children aged 3-16 years.

The muscarinic receptor antagonist has been approved in the US for.....

Lupin has reported a 21% increase in net sales to Rs13.12 billion ($280.6 million) for the first quarter ended 30 June, led by strong growth in the formulations business in the US and Europe. Net profit rose by 40% to Rs1.96 billion.

US and.....

Regeneron Pharmaceuticals has balanced a 71% rise in its second-quarter net loss to $25.5 million by securing an extension to its VelocImmune technology licensing agreement with Astellas.

Astellas non-exclusively licensed.....

Hutchison China MediTech (Chi-Med) is edging closer to spinning off its drug R&D division as it posted another solid set of results, with group sales in the first half of 2010 up by 29% to $73.2 million compared with the first half last.....

Consolidated net pharmaceutical sales at Japan's Kyowa Hakko Kirin edged up by 2% to ¥103.5 billion ($1.18 billion) in the first half to 30 June, in spite of the constraining effect of the general Japanese reimbursement price cut in.....

Drug marketing authorisation holders have until 1 August to submit applications to the UK Medicines and Healthcare products Regulatory Agency to make any labelling changes that might be required for their products to remain in accordance with the.....

A new £50 million fund should give patients in England better access to cancer drugs recommended by their doctors, announced health secretary Andrew Lansley yesterday. The news comes alongside the publication of a report that shows that the uptake of.....

A US federal judge has decided to hold a hearing on 17 August relating to Sanofi-Aventis 's lawsuit, which "seeks a temporary restraining order and a preliminary injunction requiring [the US] FDA to withdraw its approval" of the ANDA for.....